1 Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK Clinical 2 Practice Research Datalink Aurum: A reference trial (ARISTOTLE) emulation study 3 Emma Maud Powell<sup>1\*</sup>, Usha Gungabissoon<sup>2</sup>, John Tazare<sup>3</sup>, Liam Smeeth<sup>1</sup>, Paris J Baptiste<sup>4</sup>, Turki M 4 Bin Hammad<sup>1,5</sup>, Angel YS Wong<sup>1</sup>, Ian J Douglas<sup>1</sup>, Kevin Wing<sup>1</sup> 5 <sup>1</sup> Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population 6 Health, London School of Hygiene and Tropical Medicine, London, United Kingdom 7 <sup>2</sup> Epidemiology, GSK, London, United Kingdom 8 <sup>3</sup> Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of 9 Hygiene and Tropical Medicine, London, United Kingdom 10 <sup>4</sup> Clinical Effectiveness Group, Centre for Primary Care, Wolfson Institute of Population Health, Barts 11 and The London School of Medicine and Dentistry, Queen Mary University of London, London, 12 **United Kingdom** 13 <sup>5</sup> Methodology and biostatistics team, Department of Efficacy and Safety, Drug sector, Saudi Food 14 and Drug Authority, Riyadh, Saudi Arabia 15 The views expressed in this paper are those of the author and not do not necessarily reflect those of 16 the SFDA or its stakeholders. Guaranteeing the accuracy and the validity of the data is a sole

19 \* Corresponding author

17

18

20 E-mail maud.teoh@lshtm.ac.uk (EMP)

responsibility of the research team.

**ABSTRACT** 22 Background 23 Stroke prevention treatment guidance for patients with atrial fibrillation (AF) uses evidence 24 generated from randomised controlled trials (RCTs). However, applicability to patient groups 25 excluded from trials remains unknown. Real-world patient data provides an opportunity to evaluate 26 outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients 27 otherwise excluded from RCTs, however there remains uncertainty on the validity of the methods 28 and suitability of the data. 29 Successful reference trial emulation can support the generation of evidence around treatment 30 effects in groups excluded or underrepresented in the original trials. 31 We used linked UK primary care data to investigate whether we could emulate the pivotal 32 ARISTOTLE trial (apixaban vs warfarin) and extend the analysis to investigate the impact of warfarin 33 time in therapeutic range (TTR) on results. 34 Methods and findings 35 Patients with AF in a UK primary care database Clinical Practice Research Datalink (CPRD Aurum) 36 prescribed apixaban or warfarin from 1 Jan 2013 to 31 Jul 2019 were selected. ARISTOTLE eligibility 37 criteria were applied to this population and matched to the RCT apixaban arm on baseline 38 characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to 39 warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional 40 hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up 41 and results benchmarked against the trial results before treatment effectiveness was further 42 evaluated based on (warfarin) time in therapeutic range (TTR). 43 The analysis sample comprised 8734 apixaban users and propensity-score matched 8734 warfarin 44 users in CPRD. Results [Hazard Ratio (95% Confidence Interval)] confirmed apixaban non-inferiority

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) vs trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) vs trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for Stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year) whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year) Analysis by TTR suggested non-inferiority of apixaban in those with TTR < 0.75 [Stroke/SE 0.94 (0.75,1.19), all-cause death 0.99 (0.87,1.12)]. However, apixaban was associated with increased hazards compared with well-controlled warfarin treatment (TTR ≥ 0.75) [Stroke/SE 1.49 (1.13,1.97), all-cause death 1.75 (1.49,2.06)]. The main limitation of the study's methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm. Conclusions Analysis of non-interventional data generated results demonstrating non-inferiority of apixaban vs warfarin consistent with the pre-specified benchmarking criteria. Unlike in ARISTOTLE superiority of apixaban vs warfarin was not seen which may be linked to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. The methodological template developed can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or under-represented in trials and also provides a

framework which can be adapted to investigate treatment effects for other conditions.

**AUTHOR SUMMARY** 

Why Was This Study Done?

- Stroke prevention treatment guidelines for patients with atrial fibrillation (AF) are based on results from randomised controlled trials (RCTs), we do not know if these results are relevant to patients that would not have been eligible to be included in the RCTs.
- This study used routinely collected health data from the UK to emulate an RCT that
  compared apixaban to warfarin, ARISTOTLE, and also looked at whether the benefit of
  apixban compared with warfarin was impacted by the quality of warfarin therapy (measured
  by time in therapeutic range, TTR).
- Emulating an RCT for stroke prevention in patients with AF should help to understand how
  transferable RCT results are to 'real-world' practices and whether this methodological
  approach can help to improve treatment options and outcomes for patient groups currently
  underrepresented in clinical trials.

## What Did the Researchers Do and Find?

- The researchers looked at patients with AF in a UK primary care data prescribed apixaban or
  warfarin and applied a "reference trial emulation" approach, in which the ARISTOTLE trial
  eligibility, selection and analysis approaches were applied to UK primary care data and
  results benchmarked against those of ARISTOTLE.
- Patients prescribed apixaban had similar rates of outcomes to those prescribed warfarin in our cohort and our results were successfully benchmarked against ARISTOTLE. Unlike
   ARISTOTLE we did not see superiority of apixaban vs warfarin [Hazard ratio (95% confidence interval)] for time to stroke or systemic embolism: 0.98 (0.82,1.19) in our cohort vs 0.79
   (0.66,0.95) in ARISTOTLE.
- We also found the benefit of apixaban vs warfarin differed depending on the quality of warfarin therapy with apixaban superior to poorly controlled warfarin therapy (TTR < 0.75)

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

[Stroke/SE 0.94 (0.75,1.19), Death 0.99 (0.87,1.12)] whereas apixaban was not superior to well-controlled warfarin (TTR ≥ 0.75) [Stroke/SE 1.49 (1.13,1.97), Death 1.75 (1.49,2.06)]. What Do These Findings Mean? Our results support the NICE guidelines on selecting treatment for stroke prevention in patients with AF and also provide reassurance on continuing warfarin in patients with high TTR. We can use UK primary health care data to emulate a reference trial of treatments for the prevention of stroke in AF. We can use the data and methods to look at how well treatments work in patients that would not have been included in RCTs such as those with multimorbidity or patient groups under-represented in RCTs such as ethnic minority groups and older patients. Study limitations include the possibility of residual confounding, a risk patients doing well on warfarin were over-represented in our cohort, and a lower proportion of Asian participants in our cohort compared with ARISTOTLE. Introduction Atrial fibrillation (AF) is a common type of cardiac arrhythmia with an estimated prevalence of 3.3% in UK adults aged ≥ 35 years [1]. AF is a risk factor for stroke; patients with AF have a five-fold increased risk of stroke compared with people without AF [2] and around a quarter of all strokes are attributed to this arrhythmia [3]. In addition, increased levels of mortality, morbidity and disability with longer hospital stays are observed in stroke patients with AF compared with stroke patients without AF [4, 5]. Pharmacological therapy recommended to reduce the risk of stroke in AF includes the use of oral anticoagulants (OACs). The introduction of direct oral anticoagulants (DOACs) for AF since 2012 in the UK provided a choice of treatment alongside the older OAC class of vitamin K antagonists (VKA),

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

such as warfarin which has been available for over 60 years. The VKA OACs require regular monitoring of international normalised ratio (INR) to keep patients in the optimal therapeutic range (typically 2.0 to 3.0) in which risk of both ischemic and bleeding events are minimised [6]. A patient may require dose adjustments to stay within their INR target range. A key measure of quality of warfarin treatment is therefore the time in therapeutic range (TTR) which estimates the proportion of time a patient has spent with INR within optimal range. A TTR of 0.75 or greater is often considered as indicating optimal INR control and suggests a patient is spending a high proportion of their time in their INR target range. ARISTOTLE was a pivotal RCT of the DOAC apixaban designed to demonstrate non-inferiority compared with warfarin in the prevention of stroke or systemic embolism (SE) in patients with AF. The results demonstrated superiority of apixaban over warfarin for both prevention of stroke/SE and safety (major bleeding) [7]. Results in the EU patient subset from the trial suggested the observed superiority of apixaban might be dependent on how well warfarin therapy was managed in the comparator group [8], an analysis that has not yet been performed outside of trial settings. In the NICE review of ARISTOTLE, several professional groups noted the TTR of warfarin users in ARISTOTLE may be lower than what is typical in UK clinical practice [9]. Treatment guidelines for DOACs are based on evidence from randomised controlled trials (RCTs), however, it is unclear whether these results extend to patient groups typically excluded from trials such as those with increased bleeding risk or severe comorbidities. Whilst there have been a number of previous studies of DOAC effectiveness using non-interventional data, there remains uncertainty on whether the data sources and methods used have fully accounted for the lack of treatment randomisation and issues such as selection bias and confounding. Comparing results from real-world studies with RCT results is challenging due to differences in patient populations, treatment adherence, and study design. However, reference trial emulation involves use of an existing named RCT to (1) inform observational study design and (2) benchmark results against, providing

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

confidence in validity of the selected observational methods and data. [10-13]. The noninterventional analysis methods can then be applied, under a set of assumptions, to reliably estimate effects in groups of patients with AF who would have been excluded from (or underrepresented in) the reference trial [14] such as patients aged > 80 that were under-represented in ARISTOTLE compared with patients with AF in UK clinical practice and patients with increased bleeding risk that were excluded by the trial eligibility criteria. There is increasing interest in trial emulation using observation data, and in the application of recent developments in pharmacoepidemiology methods involving the inclusion of prevalent users. This study used a framework which involved coarsened exact matching to select patients matching the trial population on aggregate, and sampling of prevalent users in a way that avoids selection bias and emulates the process of screening into an RCT, to construct a cohort of patients similar to the target trial population which included both new and prevalent users. This methodological approach could be adapted to a variety of treatments and different therapeutic areas. This study sought to (1) create an ARISTOTLE-analogous cohort using routinely collected primary and secondary care data in the UK (2) benchmark results obtained in the ARISTOTLE-analogous cohort with ARISTOTLE results and (3) explore whether apixaban treatment-effects in clinical practice are influenced by how well warfarin therapy is controlled. Materials and methods This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist). Study design A propensity score matched cohort study with emulation of a reference trial (ARISTOTLE). Setting/data sources

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

**UK Electronic Healthcare Records** This study used non-interventional data from UK Clinical Practice Research Datalink (CPRD) Aurum, a database containing anonymised data from 738 primary care practices across England (approximately 13% of the population of England with 19 million patient records and 7 million active as of September 2018 [15]. CPRD Aurum contains information on clinical diagnoses, prescribing, referrals, tests and demographic/lifestyle factors and is representative of the population of England in geographical spread, social deprivation, age and sex [15]. This study also used 2 additional data sources linked to CPRD Aurum: Hospital Episodes Statistics (HES) data, which contains data on patients admitted to NHS hopsitals including diagnoses, admission and discharge, and Office of National Statistics (ONS) mortality data. The reference trial (ARISTOTLE) ARISTOTLE was a randomised, double-blind trial completed in 2011, comparing apixaban with warfarin in the prevention of stroke and SE. The trial included 18201 patients with AF and at least one additional risk factor for stroke. The trial was designed to test for non-inferiority of apixaban compared with warfarin (non-inferiorirty margin of 1.38 for the upper limit of the 95% CI of the hazard ratio for the primary outcome), and showed apixaban superiority for (1) the primary outcome of stroke or SE (HR 0.79; 95% CI 0.66, 0.95),7 (2) the safety endpoint of major bleeding (HR 0.69; 95% CI 0.60, 0.80), and (3) death from any cause (HR 0.89; 95% CI 0.80, 0.99). The ARISTOTLE findings led to the National Institute for Health and Care Excellence (NICE) guidelines on stroke prophylaxis in patients with AF recommending apixaban as a treatment. ARISTOTLE eligibility criteria and summary baseline patient characteristics were used to select a cohort of patients from CPRD Aurum analogous to the ARISTOTLE participants.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

The use of CPRD and ARISTOTLE are described in a previous publication [14] and use of CPRD for this project was approved by the MHRA Independent Scientific Advisory Committee [ISAC protocol in S2]. All data used in this study were anonymised. Diagnostic and therapeutic codelists All diagnostic and therapeutic codelist files used are available at https://datacompass.lshtm.ac.uk/id/eprint/3590/. **Patient Selection** Step 1: application of trial eligibility criteria to patients in CPRD We first selected HES-linked patients registered in CPRD Aurum between January 1, 2013 and July 31, 2019, who had at least 6 months between registration and the index date. ARISTOTLE recruited both new (warfarin-naïve) and prevalent (warfarin-experienced) users of warfarin with randomisation stratified on prior warfarin (or other VKA) exposure status (warfarin naïve or experienced). To be classified as warfarin-naïve patients were required to have no evidence of exposure to warfarin or other VKA in the 5 years prior to the index date. To enable selection of a similar cohort of patients in CPRD Aurum (including both new and prevalent users of warfarin), the following process was used in determining index date: - apixaban users index date = first prescription of apixaban in the study period apixaban user classified as warfarin-naïve or warfarin-experienced at this date; - warfarin users for new users of warfarin: index date = first prescription of warfarin in the study period; for prevalent users of warfarin: a pool of potential index dates was selected containing all

perpetuity.

It is made available under a CC-BY 4.0 International license .

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

prescription dates in the study period, with index date selected at the later treatment-history sampling stage (see step 3). ARISTOTLE eligibility criteria (supplementary table A2) [7] were applied giving a trial-eligible cohort for apixaban users, a trial-eligible cohort of new users of warfarin, and a pool of potential index dates (with all potential index dates kept in regardless of ARISTOTLE eligibility at this stage) for warfarin continuers (prevalent warfarin users). Step 2: selection of apixaban trial-analogous patients in CPRD We selected a subset of the CPRD Aurum trial-eligible apixaban patients that better matched the ARISTOTLE apixaban participants based on aggregate summaries for the following key ARISTOTLE baseline characteristics: Age Sex Congestive heart failure or left ventricular systolic dysfunction Hypertension requiring treatment Diabetes mellitus Prior stroke/transient ischaemic attack (TIA)/systemic embolism (SE) Level of renal impairment Prior VKA/warfarin exposure To characterise the baseline patient characteristics of ARISTOTLE, we used the key publication of the trial results [7], discussion of trial results by regulatory bodies [8, 9, 16] and publications on the trial presenting cross-tabulations on key characteristics [17,18]. An ARISTOTLE-analogous cohort of CPRD Aurum apixaban patients was then selected using a modified form of coarsened exact matching [19] (see Appendix for details).

Step 3: matching of apixaban trial-analogous patients to warfarin trial-eligible patients in CPRD

To emulate ARISTOTLE which stratified randomisation on prior VKA exposure status, patients in the CPRD cohort were matched separately within the VKA-naïve and VKA-experienced strata. A 3-step procedure, based on methods proposed by Suissa et al [20] and Webster Clark et al [21], was used to select and match patients in the VKA-experienced strata whilst avoiding selection bias; this procedure is sumamrised in Figure 1 and described in in S3 Appendix.

The trial-analogous CPRD Aurum apixaban patients were matched to warfarin CPRD Aurum patients using greedy nearest-neighbour matching on the logit of the propensity score (PS); a caliper of 0.2 times the standard deviation of the logit of the propensity score was used for matching as recommended by Austin [22].

The covariates included in the propensity score models are detailed Table 1.

## **Table 1: Covariates Included in the Propensity Score Models**

Category	Variable List
Demographics	age, sex, ethnicity
CHADS <sub>2</sub> stroke risk factors	congestive heart failure or left ventricular systolic
	dysfunction, hypertension requiring treatment, diabetes
	mellitus, prior stroke/TIA/systemic embolism
Vascular stroke risk factors	prior myocardial infarction, peripheral artery disease,
	aortic plaque, history of pulmonary embolism or deep
	vein thrombosis
Other risk factors	body mass index, systolic blood pressure, history of
	bleeding, smoking status, alcohol consumption,
	socioeconomic status (imd2105_5), ethnicity
Concomitant medications	aspirin, clopidogrel, NSAIDs, antacids, statins, angiotensin-
	converting enzyme inhibitors (ACEIs) or angiotensin
	receptor blockers (ARBs), beta blockers, calcium channel
	blockers, statins, amiodarone, digoxin, proton pump
	inhibitors, H2 receptor antagonist
Comorbidities	renal function, history of fall,
	Charlson comorbidity components [COPD, connective
	tissue disease, peptic ulcer disease, liver disease,
	hemiplegia, cancer, haematological cancer], healthcare
	utilization [number of GP consults in the prior year,
	number of hospitalizations in the prior year]

AF factors	time since AF diagnosis, history of valvular disease, history
	of valvular surgery
Healthcare utilisation	number of GP consults in the prior year, number of
	hospitalizations in the prior year

AF=atrial fibrillation; COPD=chronic obstructive pulmonary disease; GP=general practicioner; NSAIDs=non-steroidal anti-inflammatory drugs; TIA=transient ischemic attack;

243

244

245

246

247

248

249

250

The model resulting in the most balanced cohort was chosen with balance assessed by looking at standardised differences across all variables after matching using a target threshold of 0.05 for the maximum difference allowed for any individual variable. Balance of covariates considered to be most important in predicting outcome were prioritised namely age, sex, and stroke risk factors.

251	Figure 1: Matching of apixaban trial-analogous patients to warfarin trial-eligible
252	patients
253	* This method has been found in a simulation study (Webster-Clark et al [21]) to
254	give unbiased results
255	CPRD=Clinical Practice Research Datalink; RCT=randomised controlled trial;
256	VKA=vitamin K antagonist.

## **Exposures and outcomes**

**Exposures** 

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

276

Exposure to apixaban (5mg/2.5mg) or warfarin was determined using CPRD prescribing records with

no restrictions on the dose prescribed.

Outcomes

The primary effectiveness outcome was the composite of stroke (ischemic or haemorrhagic) or systemic embolism (SE); individual components of this outcome (stroke, ischemic or uncertain type of stroke, haemorrhagic stroke, SE) and death from any cause were the key secondary effectiveness outcomes. Secondary effectiveness outcomes included myocardial infarction (MI), pulmonary embolism or DVT, and composite endpoints of effectiveness outcomes. The primary safety outcome was major bleeding (including by location – intracranial, gastrointestinal, or other location such as urinary or gynaecological). All outcomes involved hospitalisation or death and were ascertained using HES and ONS data. The ICD-10 codes used in ascertaining stroke occurrence have been recommended as having high positive predictive value [23].

Statistical analysis

## **Methods of Analysis**

A prospective protocol was published prior to the analysis detailing the planned analyses [14, also in

Appendix].

275 Changes from the planned protocol are described in Table 2.

# **Table 2: Changes from Planned Analyses**

Original Planned Analysis	Updated Analysis	Reason for change
Patients to be selected from both CPRD GOLD and CPRD Aurum.	Only CPRD Aurum used.	There was a much larger sample size available in CPRD Aurum meaning combining of the 2 data sources was not required.
Censoring scheme to censor at 5 years after index date.	Censoring scheme censored at 2.5 years after index date.	The ARISTOTLE trial had median duration of follow-up of 1.8 years (IQR

		1.4, 2.3) therefore a 2.5 year cut-off gives a more similar duration of follow-up than 5 years.
Adherence of apixaban users to be measured by proportion of days covered by prescriptions.	Treatment persistence measured instead (proportion of patients still on index treatment at date of censoring).	Repeat prescriptions are often issued automatically meaning comparing number of days covered by prescribed pills to the number of days in the treatment period did not provide useful insight on adherence.
Supplementary analysis in patients deemed adherent (PDC ≥ 80%, ARISTOTLE compliance limit).	Analysis by TTR only.	Unable to ascertain useful measure of adherence in the apixaban users.
Non-inferiority will be concluded when the upper limit of the 95% CI for the hazard ratio must be less than 1.52 (upper limit in the EU subgroup of ARISTOTLE).	Non-inferiority will be concluded when the upper limit of the 95% CI for the hazard ratio is less than 1.38 (same non-inferiority margin of ARISTOTLE).	The non-inferiority margin used in ARISTOTLE was the one agreed by regulators to represent the maximum acceptable clinical difference. By applying the same margin, we ensure that the conclusion is based on more rigorous criteria.
Aim to include prior INR control in propensity model for vitamin k antagonist-experienced patients.	Primary analysis does not include prior INR control. Post hoc sensitivity analysis performed including prior INR control in the propensity score model.	High rate of missing data for prior INR control made it not advisable to include this variable in the propensity score model for the main analysis. Other variables predictive of poor INR control such as age are already included. Post hoc sensitivity analysis including INR control in the propensity score model performed to assess the potential impact of not including this variable following question in peer review on the omission of this variable.
N/A	Post hoc analysis assessing apixaban dose-adjustment in CPRD Aurum	Suggested by peer review to provide evidence on the quality of dose adjustment in CPRD Aurum and how this may impact the results in the trial-analogous cohort.

All time-to-event endpoints were analysed using a Cox proportional hazards model, stratified by prior VKA status (experienced, naïve). The effectiveness outcomes were analysed using the intention-to-treat principle and major bleeding was analysed using an on-treatment censoring scheme. Patients were censored at 2.5 years after index date reflecting typical maximum duration of follow-up in ARISTOTLE. Cluster-robust standard errors were used with pair membership as the clustering variable [24,25]. The proportional hazards assumption was assessed by looking at the log-

277

278

279

280

281

282

283

log of the Kaplan-Meier survival curves and inspection of scaled Schoenfeld residuals plotted against time. Analyses were performed using SAS version 9.4 and R version 4.2.1.

# Supplementary analyses

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

A protocol planned analysis in the subset of patients deemed adherent (with adherence measured by TTR in the warfarin users and by proportion of days covered by prescriptions in the apixaban users) was planned to assess the impact of adherence on outcomes. The planned analysis was not possible due to the apixaban prescription data not providing a useful measure of adherence. An analysis by INR TTR was performed instead to assess the impact of warfarin control on results with all outcomes analysed by TTR (TTR < 0.75 and TTR ≥ 0.75). In order to perform the TTR analysis whilst maintaining balance in the baseline covariates, inverse probability treatment weighting (IPTW) was used to rebalance the baseline characteristics, applying stabilised weights to the ARISTOTLE-analogous apixaban users. A similar approach to the main analysis was used with propensity score models constructed separately for the new users and warfarin-experienced users. An additional post hoc analysis was performed looking at the proportion of apixaban patients prescribed reduced-dose apixaban along with a comparison of the patients meeting the criteria for dose-reduction against the dose actually prescribed. In this analysis apixaban dose in the ARISTOTLEanalogous CPRD cohort was assessed and compared against the ARISTOTLE protocol-specified criteria and NICE criteria for reduced apixaban dose. ARISTOTLE specified that participants meeting any 2 of the following criteria assessed at the time of randomisation should have their apixaban dose reduced to 2.5mg BID: age  $\geq$  80 years, body weight  $\leq$  60 kg, or serum creatinine  $\geq$  1.5 mg/dL. These criteria are equivalent to the NICE guidelines for dose reduction with NICE having an additional criteria indicating reduced dose in those with creatinine clearance 15-29 mL/minute. In addition, to assess the impact of the quality of dose-adjustment in the CPRD cohort on the observed effectiveness of apixaban relative to warfarin, a supplementary post hoc analysis was

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

performed looking at the results in the subset of apixaban patients prescribed the correct dose compared with IPTW re-balanced warfarin comparators. **Sensitivity analyses** Primary and secondary effectiveness outcomes were also analysed using the on-treatment censoring scheme to investigate whether treatment discontinuation compromises confidence in the effectiveness analyses. Treatment persistence was defined by looking at longitudinal prescription data for OACs; OAC treatment windows were derived in which gaps >= 6 months between prescription dates were considered as distinct treatment windows. The end of each OAC treatment window was derived as the date of the last prescription of index OAC + the number of days supply given in the last prescription + a grace period of 30 days. In cases of overlapping OAC treatment windows the date of the first prescription of the subsequent OAC treatment window was used to define the end of the prior OAC window. A prescription for a different OAC from the index OAC treatment was considered as a treatment switch. An ending of index OAC treatment with no subsequent prescription for any other OAC recorded was considered as treatment stop. Gaps of >= 6 months with no subsequent OAC prescriptions recorded were categorised as having stopped OAC treatment. The set of patients who switched or discontinued treatment during follow-up were examined to ascertain whether selection bias due to attrition may have affected the on-treatment analyses (Table A9 in Appendix). Apixaban was first launched for AF in the UK in January 2013, with relatively few patients receiving a prescription in the first year it was available; we therefore performed a sensitivity analysis with the start of study period shifted forwards a year to investigate the impact of inclusion of early adopters who may differ from later adopters of a new drug.

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

no formal criteria or hypothesis testing used.

**Confounding and bias** In the study period apixaban was a newly available treatment leading to the possibility of channelling bias [26]. By applying trial eligibility criteria to both treatment cohorts and matching using baseline covariates we aimed to minimise channelling bias. To handle confounding, treatment arms were matched using PSM [27]. Benchmarking results against ARISTOTLE The study hypothesis was that results in the CPRD ARISTOTLE-analogous cohort would be comparable to the ARISTOTLE results, as defined by the pre-specified benchmarking criteria. A slightly weaker benefit of apixaban vs warfarin was expected based on the weaker benefit seen in the EU subgroup of ARISTOTLE and an expectation that the quality of warfarin control in UK patients may be higher than that observed in ARISTOTLE. The benchmarking criteria for considering the results in the trial-analogous CPRD cohort to be comparable with ARISTOTLE were pre-specified and published previously [14]: 1. The effect size must be clinically comparable with the ARISTOTLE findings; the HR for time to stroke/SE with the HR must be between 0.69 and 0.99. This range is not symmetrical around the ARISTOTLE estimate of 0.79 as it is anticipated the treatment effect in routine clinical care may be weaker than that seen in the optimised setting of a clinical trial. 2. The upper limit of the 95% CI for the HR for time to stroke/SE must be less than 1.38 (noninferiority margin used in ARISTOTLE, updated since protocol – see Table 2). The benchmarking step applied only to the primary effectiveness outcome in the trial-analogous CPRD cohort; results in other groups such as patients underrepresented or excluded from the trial would not necessarily be expected to remain consistent to the RCT results given the relative risks may differ in these groups. Comparability of other outcomes was to be assessed descriptively with

Missing data

Patients with missing systolic blood pressure (0.1%), body mass index (3.3%), smoking status (0.1%), or socioeconomic status (0.1%) were excluded from the trial-eligible cohort as the proportion of patients with these missing was low. Patients with missing renal function (1.3%), ethnicity (0.4%), or alcohol use (5.6%) were kept in the cohort through a missing indicator approach; this approach is valid under the assumption that these variables act as confounders and influence clinician prescribing decisions only when observed [28]. A total of 1176 (13.3%) warfarin users in the CPRD cohort did not have INR measurements in the data during their treatment period and were not included in the analysis by TTR.

#### **Ethics**

Scientific approval was provided by the London School of Hygiene and Tropical Medicine research ethics committee (ref 17682) and the independent scientific advisory committee of the Medicines and Healthcare Products Regulatory Agency (protocol no. 19\_066R). CPRD data are already approved via a national research ethics committee for purely non-interventional research of this type. CPRD data are analysed anonmymously therefore individual patient consent is not sought by contributing medical practices when data is shared with CPRD; however, patients are able to opt out of their patient information being shared for research.

#### Results

## **Participants**

Between January 1, 2013 and July 31, 2019 there were 86,888 people with AF prescribed apixaban and 159,632 prescribed warfarin in HES-linked CPRD Aurum practices (Figure 2). Application of minimum registration period and ARISTOTLE inclusion criteria reduced this to 67,539 apixaban and 139,527 warfarin patients. After applying ARISTOTLE exclusion criteria there were 41,487 apixaban and 101,159 warfarin patients.

perpetuity.

It is made available under a CC-BY 4.0 International license .

380

381

382

383

384385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

Selecting apixaban patients to match ARISTOTLE on key baseline characteristics yielded 9,120 apixaban patients (3,912 new users and 5,208 prevalent users) available for propensity score matching to 101,159 warfarin patients. For 274 apixaban patients no match could be found giving a propensity score matched cohort of 8846 apixaban and 8846 warfarin patients. Figure 2: Selection of ARISTOTLE-analogous CPRD Aurum Cohort Flow of number of individuals included in the analysis. AF = atrial fibrillation; ALT = alanine transaminase; AST = aspartate transaminase; BMI = body mass index; BP = blood pressure; CPRD = Clinical Practice Research Datalink; HES: Hospital Episodes Statistics; Rx = Prescription; SES = socioeconomic status; ULN = upper limit of normal; VKA = vitamin K antagonist. a Severe comorbid condition with life expectancy <1 year or reasons making participation impractical; b ALT or AST > 2X ULN or Total Bilirubin ≥ 1.5X ULN; c Pregnant or breastfeeding within 3 vears prior See supplementary table A1 in S3 Appendix for detailed list of inclusion and exclusion criteria. Note: For prevalent warfarin users trial eligibility only revealed at point of random selection into the cohort for prevalent users. Numbers in figure show maximum theoretical number of warfarin users available should they be selected only at a time they were eligible for the trial. Application of ARISTOTLE inclusion/exclusion criteria and matching to ARISTOTLE Applying the ARISTOTLE inclusion/exclusion criteria and matching to ARISTOTLE baseline patient characteristics resulted in a cohort similar to the ARISTOTLE apixaban participants (Table 3); for example median age was 78 and mean CHADS<sub>2</sub> score 2.4 in CPRD Aurum before applying trial criteria and matching whereas the median age of 71 and mean CHADS<sub>2</sub> score 2.1 after these steps matched the ARISTOTLE apixaban participants. The ARISTOTLE-analogous apixaban arm matched the trial arm on prior VKA exposure, age, sex, stroke risk factors and CHADS<sub>2</sub> score, and proportion of patients with moderate or severe renal impairment. Differences remained on baseline characteristics it was not feasible to match on namely: ethnicity (95.2% white, 2.4% Asian in CPRD Aurum apixaban vs 82.6% white, 14.4% Asian in ARISTOTLE) and concomitant medications (amiodarone 3.8%, aspirin 5.8%, digoxin 13.9% in CPRD Aurum apixaban users vs amiodarone 11.1%, aspirin 31.3%, digoxin 32.0% in ARISTOTLE apixaban arm). See Appendix for details on matching feasibility.

411 Propensity score matching of CPRD Aurum trial-analogous apixaban users to CPRD Aurum warfarin 412 users 413 **Results of Propensity score matching** 414 Before propensity score matching, differences between treatment groups were evident for most 415 baseline variables including age (median age 71 in apixaban vs 78 in warfarin), sex (apixaban 35.6% 416 female vs warfarin 43.6%), and stroke risk factors [see Table 3]. After propensity score matching all 417 baseline characteristics were well balanced (maximum standardised difference .031). From 9120 418 apixaban users only 274 (3.0%) were dropped due to unsuccessful matching.

CPRD Aurum ARISTOTLE Trial

			<u>'</u>	CPKD Aurum				ANISTO	ILE IIIdi
	No ARISTOTI or matching	LE criteria	After applying ARISTOTLE of	_		ng ARISTOTLE the trial and warfarin			
Characteristic - n(%) unless specified	Apixaban (N=73 843)	Warfarin (N=146 332)	Apixaban (N=41 487)	Warfarin (N=101 159)	Apixaban (N=8 846)	Warfarin (N=8 846)	Standardis ed difference	Apixaban (N=9 120)	Warfarin (N=9 081)
Age – years , median (IQR)	78 (70, 85)	78 (71, 84)	78 (71, 84)	78 (72, 84)	71 (63, 77)	71 (63, 77)	0.008	70 (63, 76)	70 (63, 76)
Female sex	34 430 (46.6)	63 321 (43.3)	19 591 (47.2)	44 197 (43.7)	3144 (35.5)	3190 (36.1)	0.011	3 234 (35.5)	3 182 (35.0)
Systolic blood pressure – mmHg, median (IQR)	130 (120, 140)	130 (120, 140)	131 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	0.001	130 (120, 140)	130 (120, 140)
Missing Weight – kg, median (IQR)	132 79 (67, 92)	267 80 (68, 93)	60 80 (68, 93)	125 80 (69, 94)	0 85 (73, 100)	0 85 (74, 99)	0.003	82 (70, 96)	82 (70, 95)
Prior myocardial infarction	9 958 (13.5)	20 406 (13.9)	5 035 (12.1)	13 446 (13.3)	1090 (12.3)	1074 (12.1)	0.006	1319(14.5)	1266 (13.9)
Prior clinically relevant or spontaneous bleeding	16 972 (23.0)	31 034 (21.2)	7 721 (18.6)	19 007 (18.8)	1533 (17.3)	1507 (17.0)	0.008	1525 (16.7)	1515 (16.7)
History of fall within previous year	2 443 (3.3)	2 688 (1.8)	1 093 (2.6)	1 561 (1.5)	137 (1.5)	131 (1.5)	0.006	386 (4.2)	367 (4.0)
Prior use VKA >30 days	24 240 (32.8)	102 725 (70.2)	12 558 (30.3)	75 787 (74.9)	4944 (55.9)	4944 (55.9)	0.000	5 208 (57.1)	5 193 (57.2)
Qualifying risk factors									
Age ≥ 75 years	45 762 (62.0)	93 436 (63.9)	26 730 (64.4)	68 197 (67.4)	2 770 (31.3)	2 740 (31.0)	0.007	2 850 (31.2)	2 828 (31.1)
Prior stroke, TIA, or SE	20 713 (28.1)	38 132 (26.1)	11 422 (27.5)	25 898 (25.6)	1 711 (19.3)	1 709 (19.3)	0.001	1 748 (19.2)	1 790 (19.7)
Heart failure or reduced LVEF	22 329 (30.2)	50 480 (34.5)	11 650 (28.1)	33 422 (33.0)	3 052 (34.5)	3 022 (34.2)	0.007	3 235 (35.5)	3 216 (35.4)
Diabetes	20 104 (27.2)	40 103 (27.4)	11 630 (28.0)	28 496 (28.2)	2 243 (25.4)	2 275 (25.7)	0.008	2 284 (25.0)	2 263 (24.9)
Hypertension req. treatment	52 406 (71.0)	105 097 (71.8)	31 780 (76.6)	76 923 (76.0)	7 662 (86.6)	7 669 (86.7)	0.002	7 962 (87.3)	7 954 (87.6)

			0.5.10				0.000		
CHADS <sub>2</sub> score, mean ± SD	2.4 ± 1.5	2.4 ± 1.4	2.5 ± 1.3	2.5 ± 1.2	2.1 ± 1.1	2.1 ± 1.1	0.003	2.1 ± 1.1	2.1 ± 1.1
CHADS <sub>2</sub> =0	6 494 (8.8)	10 240 (7.0)	134 (0.3)	356 (0.4)	52 (0.6)	55 (0.6)	0.004	54 (0.6)	58 (0.6)
CHADS <sub>2</sub> =1	14 860 (20.1)	28 124 (19.2)	10 602 (25.6)	23 539 (23.3)	2 971 (33.6)	2 912 (32.9)	0.014	3 046 (33.4)	3 025 (33.3)
CHADS <sub>2</sub> =2	19 844 (26.9)	43 294 (29.6)	12 969 (31.3)	32 980 (32.6)	3 157 (35.7)	3 239 (36.6)	0.019	3 262 (35.8)	3 254 (35.8)
CHADS <sub>2</sub> ≥3	32 645 (44.2)	64 674 (44.2)	17 783 (42.9)	44 284 (43.8)	2666 (30.1)	2640 (29.8)	0.006	2 758 (30.2)	2 744 (30.2)
Medications at index date									
ACE inhibitor or ARB	34 899 (47.3)	82 841 (56.6)	21 656 (52.2)	61 435 (60.7)	5529 (62.5)	5573 (63.0)	0.010	6 464 (70.9)	6 368 (70.1)
Amiodarone	1 903 (2.6)	4 859 (3.3)	961 (2.3)	3 259 (3.2)	336 (3.8)	322 (3.6)	0.008	1 009 (11.1)	1 042 (11.5)
Beta-blocker	46 173 (62.5)	88 274 (60.3)	25 990 (62.6)	62 016 (61.3)	6083 (68.8)	6031 (68.2)	0.013	5 797 (63.6)	5 685 (62.6)
Aspirin	5209 (7.1%)	10833 (7.4%)	2 612 (6.3)	6 429 (6.4)	514 (5.8)	557 (6.3)	0.020	2 859 (31.3)	2 773 (30.5)
Clopidogrel	2697 (3.7%)	3697 (2.5%)	1 238 (3.0)	2 177 (2.2)	229 (2.6)	215 (2.4)	0.010	170 (1.9)	168 (1.9)
Digoxin	9 771 (13.2)	33 342 (22.8)	5 147 (12.4)	23 322 (23.1)	1232 (13.9)	1244 (14.1)	0.004	2 916 (32.0)	2 912 (32.1)
Calcium channel blocker	19 659 (26.6)	39 909 (27.3)	12 522 (30.2)	30 379 (30.0)	2965 (33.5)	2994 (33.8)	0.007	2 744 (30.1)	2 823 (31.1)
Statin	39 027 (52.9)	82 086 (56.1)	23 035 (55.5)	58 647 (58.0)	5230 (59.1)	5228 (59.1)	0.000	4 104 (45.0)	4 095 (45.1)
Non-steroidal anti- inflammatory	4 953 (6.7)	8 107 (5.5)	2 939 (7.1)	5 891 (5.8)	487 (5.5)	479 (5.4)	0.004	752 (8.2)	768 (8.5)
Gastric antacid drugs	1 833 (2.5)	3 290 (2.2)	1 042 (2.5)	2 346 (2.3)	180 (2.0)	180 (2.0)	0.000	1 683 (18.5)	1 667 (18.4)
Proton pump inhibitor	2844 (38.0)	47 838 (32.7)	15 197 (36.6)	31 769 (31.4)	3052 (34.5)	3104 (35.1)	0.012		
H2 receptor antagonist	3 188 (4.3)	4 837 (3.3)	1 586 (3.8)	3 006 (3.0)	281 (3.2)	250 (2.8)	0.021		

Renal function, creatinine									
clearance									
Normal, >80 ml/min	21 591	45 793	12 261	31 451	4 098	4 074	0.005	3 761	3 757 (41.4)
	(29.2)	(31.3)	(29.6)	(31.1)	(46.3)	(46.1)		(41.2)	
Mild imp., >50 to 80	28 976	56 742	17 494	41 290	3 307	3 292	0.004	3 817	3 770 (41.5)
ml/min	(39.2)	(38.8)	(42.2)	(40.8)	(37.4)	(37.2)		(41.9)	
Moderate imp. (>30 to 50	17 007	32 881	9 708	23 316	1 276	1 306	0.010	1 365	1 382 (15.2)
ml/min)	(23.0)	(22.5)	(23.4)	(23.0)	(14.4)	(14.8)		(15.0)	
Severe imp. (≤30 ml/min)	4 317	9 251 (6.3)	1 053	4 251	126 (1.4)	132 (1.5)	0.006	137 (1.5)	133 (1.5)
	(5.8)		(2.5)	(4.2)					
Not reported	1 952	1 665 (1.1)	972 (2.3)	851 (0.8)	39 (0.4)	42 (0.5)	0.005	40 (0.4)	39 (0.4)
•	(2.6)								
Peripheral artery disease	5 984	12 764	2 770	7 516	552 (6.2)	538 (6.1)	0.007		
	(8.1)	(8.7)	(6.7)	(7.4)					
Aortic plaque	17 919	40 415	8 974	25 193	2 097	2 057	0.011		
	(24.3)	(27.6)	(21.6)	(24.9)	(23.7)	(23.3)			
Smoking status									
Non-smoker	27 568	51 612	15 949	36 338	3 186	3 164	0.005		
	(37.3)	(35.3)	(38.4)	(35.9)	(36.0)	(35.8)			
Ex-smoker	40 815	84 850	22 757	58 669	4 925	4 945	0.005		
	(55.3)	(58.0)	(54.9)	(58.0)	(55.7)	(55.9)			
Current smoker	5 236	9 658 (6.6)	2 688	6 049	735 (8.3)	737 (8.3)	0.001		
	(7.1)	, ,	(6.5)	(6.0)	, ,	,			
Missing	224	211	94	102	0	0			
•									
Alcohol consumption									
Non-drinker	27 185	52 744	14 957	35 905	2 802	2 842	0.010		
	(36.8)	(36.0)	(36.1)	(35.5)	(31.7)	(32.1)			
Light, 1 to 14 units per	32 190	66 072	18 762	46 876	4 135	4 153	0.004		
week	(43.6)	(45.2)	(45.2)	(46.3)	(46.7)	(46.9)			
Moderate, 15 to 42 units	8 950	15 916	5 053	11 109	1 563	1 515	0.014		
per week	(12.1)	(10.9)	(12.2)	(11.0)	(17.7)	(17.1)			
Heavy, > 42 units per week	1 488	2 028 (1.4)	617 (1.5)	1 149	203	204	0.001		
•	(2.0)	. ,	,	(1.1)	(2.3)	(2.3)			

Missing	3 901	9 223	2 032	5 893	143	132			
Socioeconomic status									
(England IMD2015 Quintile)									
1 (least deprived)	18 893 (25.6)	36 046 (24.6)	10 867 (26.2)	25 270 (25.0)	2 246 (25.4)	2 231 (25.2)	0.004		
2	17 203 (23.3)	33 585 (23.0)	9 768 (23.5)	23 473 (23.2)	2 098 (23.7)	2 057 (23.3)	0.011		
3	14 591 (19.8)	29 856 (20.4)	8 207 (19.8)	20 704 (20.5)	1 715 (19.4)	1 759 (19.9)	0.013		
4	12 283 (16.6)	25 614 (17.5)	6 767 (16.3)	17 498 (17.3)	1 443 (16.3)	1 465 (16.6)	0.007		
5 (most deprived)	10 804 (14.6)	21 066 (14.4)	5 843 (14.1)	14 098 (13.9)	1 344 (15.2)	1 334 (15.1)	0.003		
Missing	69	165	36	116	0	0			
Ethnicity									
White	70 703 (95.7)	141 019 (96.4)	39 685 (95.7)	97 735 (96.6)	8 424 (95.2)	8 444 (95.5)	0.011	7 536 (82.6)	7 493 (82.5)
Black	714 (1.0)	1 326 (0.9)	372 (0.9)	821 (0.8)	104 (1.2)	103 (1.2)	0.001	125 (1.4)	102 (1.1)
Asian	1 371 (1.9)	2 481 (1.7)	774 (1.9)	1 536 (1.5)	214 (2.4)	209 (2.4)	0.000	1 310 (14.4)	1 332 (14.7)
Other	198 (0.3)	356 (0.2)	113 (0.3)	232 (0.2)	22 (0.2)	22 (0.2)	0.000	149 (1.6)	153 (1.7)
Mixed	152 (0.2)	308 (0.2)	75 (0.2)	190 (0.2)	25 (0.3)	28 (0.3)	0.006	0	0
Unknown	385 (0.5)	448 (0.3)	252 (0.6)	350 (0.3)	42 (0.5)	25 (0.3)	0.031	0	0
Charlson comorbidity components									
Chronic obstructive pulmonary disease	10 324 (14.0)	19 033 (13.0)	5 411 (13.0)	12 573 (12.4)	1 138 (12.9)	1 141 (12.9)	0.001		
Connective tissue disease	5 377 (7.3)	9 784 (6.7)	3 000 (7.2)	6 744 (6.7)	536 (6.1)	534 (6.0)	0.001		

Peptic ulcer	4 400 (6.0)	8 399 (5.7)	2 161 (5.2)	5 458 (5.4)	411 (4.6)	393 (4.4)	0.010	
Liver disease	761 (1.0)	1 291 (0.9)	263 (0.6)	642 (0.6)	76 (0.9)	61 (0.7)	0.019	
Hemiplegia	265 (0.4)	559 (0.4)	147 (0.4)	379 (0.4)	24 (0.3)	16 (0.2)	0.019	
Non-haematological Cancer	12 567 (17.0)	23 383 (16.0)	6 019 (14.5)	14 413 (14.2)	1 066 (12.1)	1 146 (13.0)	0.027	
Haematological cancer	1 966 (2.7)	3 481 (2.4)	951 (2.3)	2 231 (2.2)	174 (2.0)	163 (1.8)	0.009	
BMI - kg/m², median (IQR)	28 (24, 32)	28 (23, 32)	28 (25, 32)	28 (25, 32)	29 (26, 33)	29 (26, 33)	0.003	
Missing	2 270	5 858	1 166	3 593	0	0		

Table 3: Baseline characteristics of patients with Atrial Fibrillation prescribed apixaban and warfarin in CPRD Aurum compared with ARISTOTLE participants: i) before and ii) after applying ARISTOTLE inclusion and exclusion criteria and iii) after matching to the trial participants.

ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; BMI=body mass index; CHADS₂ = stroke risk factor score based on Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, prior Stroke; CPRD = Clinical Practice Research Datalink; IMD2015= Index of Multiple Deprivation 2015; imp.=impairment; IQR=interquartile range; LVEF=left ventricular ejection fraction; PSM = propensity score matching; SD=standard deviation; SE=systemic embolism;TIA=transient ischemic attack; VKA = vitamin K antagonist;

perpetuity. It is made available under a CC-BY 4.0 International license .

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

Main results The hazard ratio (HR) for stroke/systemic embolism (SE) in the propensity score matched groups was 0.98 (95% CI 0.82,1.19) (Figure 3 and Table A3 in S3 Appendix). This association was consistent with the non-inferiority margin (upper limit of the 95% CI less than 1.38) [7] but did not show superiority as predicted by ARISTOTLE [HR 0.79 (95% CI 0.66,0.95)] (Figure 3 and Appendix Table A2 in S3 Appendix). The outcome of all-cause mortality also showed non-inferiority [Aurum 1.03 (0.93,1.14) vs trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for the primary outcome and components were close to the trial for apixaban – for example [comparing Aurum vs trial] stroke/SE event rate of 1.27%/year vs. 1.27% whereas the warfarin group had a lower event rate compared with ARISTOTLE (stroke/SE event rate of 1.29%/year vs. 1.60% and hemorrhagic stroke 0.33 %/yr vs 0.47%/yr) (Figure 3). Mean duration of follow-up in the cohort was 1.8 years in the apixaban arm and 2.2 years in the warfarin arm. Figure 3: Forest plot showing hazard ratios (dots) and 95% confidence intervals (lines) for apixaban vs warfarin. Absolute event rates (%/year) and Hazard Ratio (95% Confidence Intervals) are presented for key effectiveness outcomes in i) ARISTOTLE, ii) CPRD Aurum trial-matched cohort, iii) CPRD Aurum trial-matched with TTR<0.75, and iv) CPRD Aurum trial-matched with TTR≥0.75. Dashed line shows non-inferiority margin 1.38 for the upper bound of the 95% CI of the hazard ratio used in ARISTOTLE for the primary outcome of stroke or systemic embolism. For the analysis by TTR inverse probability of treatment weighting was applied to the apixaban users targeting the treatment effect in the warfarin users with TTR < 0.75 and TTR ≥0.75. Cl=confidence interval; CPRD=Clinical Practice Research Datalink; HR=hazard ratio; TTR=time in therapeutic range. Analysis of impact of warfarin time in therapeutic range (TTR) TTR was higher in the CPRD cohort than in ARISTOTLE (mean 0.73 vs. 0.62, median 0.76 vs 0.66). Analysis by TTR suggested non-inferiority of apixaban vs warfarin in those with TTR < 0.75 [Stroke/SE 0.94 (0.75,1.19), all-cause death 0.99 (0.87,1.12)] (Figure 3). Apixaban was associated with increased

hazards of both outcomes compared to warfarin in those with well-controlled warfarin treatment  $(TTR \ge 0.75)$  [Stroke/SE 1.49 (1.13,1.97), all-cause death 1.75 (1.49,2.06)] (Figure 3).

## Analysis of apixaban dose-adjustment

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

The proportion of patients meeting the criteria for reduced dose apixaban was similar between the CPRD ARISTOTLE-analogous apixaban, warfarin, and RCT apixaban groups (4.9%, 4.9%, and 4.7% respectively). When including the additional NICE criteria of creatinine clearance 5.1% of apixaban users in the ARISTOTLE-analogous cohort had an indication for reduced-dose apixaban yet a larger proportion (14.3%) were prescribed reduced dose apixaban implying some patients in CPRD Aurum may have been prescribed the wrong dose and/or information on criteria for dose reduction may have been missing from CPRD Aurum.

Table 4: Apixaban Dose-adjustment in CPRD Aurum compared with ARISTOTLE

	CPRD Aurum	CPRD Aurum	
	ARISTOTLE-analogous	ARISTOTLE-analogous	ARISTOTLE RCT
	Apixaban	Warfarin	Apixaban
	(N = 8846)	(N = 8846)	(N=9120)
Standard 5.0 mg BID	7580 (85.7%)	N/A	8692 (95.3%)
dose			
Reduced 2.5mg BID	1266 (14.3%)	N/A	428 (4.7%)
dose			
Reduced dose	434 (4.9%)	436 (4.9%)	428 (4.7%)
indicated per			
ARISTOTLE criteria			
Reduced dose	454 (5.1%)	459 (5.2%)	NR
indicated per NICE			
criteria			

NICE criteria for dose-adjustment included additional criteria of creatinine clearance 15-29 mL/minute. N/A=Not applicable. NR=Not reported.

A futher analysis of the quality of dose-adjustment in patients in CPRD Aurum indicated 10.5% of patients may have been prescribed an incorrect dose of apixaban at the index prescription based on the data contained in their EHRs. The majority of incorrect dose relating to patients being prescribed reduced-dose apixaban despite not meeting the criteria for dose reduction. A large proportion of patients prescribed an incorrect dose had only 1 dose adjustment criteria (59.6% of those with incorrect dose) suggesting some prescribers may have thought a dose reduction was warranted

when only 1 criteria was present. Other possible reasons for the incorrect dose-adjustment observed here may be data on the criteria missing from the EHR record (ie incorrect ascertainment) or consideration of other medical history which made a prescriber adjust the dose.

Table 5: Quality of apixaban dose-adjustment in CPRD Aurum ARISTOTLE-analogous cohort

Dose Status Against NICE Criteria For Dose-adjustment	CPRD Aurum
at Index Date	ARISTOTLE-analogous
	Apixaban
	(N = 8846)
Patients on correct dose	7921 (89.5%)
Patients on incorrect dose	925 (10.5%)
Standard 5.0 mg BID dose despite meeting criteria	59 (0.7%)
for dose reduction	
Reduced 2.5mg BID dose despite not meeting	866 (9.8%)
criteria for dose reduction	
0 dose adjustment criteria recorded in EHR	313 (3.5%)
1 dose adjustment criteria recorded in EHR	553 (6.3%)
Age > 80 years	389 (4.4%)
Body weight ≤ 60 kg	57 (0.6%)
Serum creatinine ≥ 1.5 mg/dL	107 (1.2%)

To assess the impact of the quality of dose-adjustment in the CPRD cohort on the effectiveness of apixaban a supplementary post hoc anlaysis was performed looking at the results in the subset of apixaban patients prescribed the correct dose (N=7921) compared with IPTW re-balanced warfarin comparators. The results in this subset were consistent with the primary results showing apixaban to be non-inferior to warfarin (Stroke/SE 0.96 [0.78,1.17], death 0.97 [0.87,1.09]) with the results moving slightly closer to those observed in ARISTOTLE.

## Safety results

The analysis for safety outcomes is presented in Figure 4 and Table A5 in S3 Appendix; patients on apixaban had a lower risk of major bleeding compared with those on warfarin, HR (95% CI) 0.88 (0.77,1.00), consistent with ARISTOTLE. Analysis by TTR suggested superiority of apixaban for major bleeding in those with TTR <0.75 [0.70 (0.59,0.82)] whereas apixaban users had a higher risk of major bleeding compared with those with optimal warfarin control (TTR  $\geq$  0.75) [1.31 (1.08,1.59)].

perpetuity.
It is made available under a CC-BY 4.0 International license .

485

486

487

488

489

490

491

492

493

494

495 496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

Figure 4: Forest plot showing hazard ratios (dots) and 95% confidence intervals (lines) for apixaban vs warfarin. Absolute event rates (%/year) and Hazard Ratio (95% Confidence Intervals) are presented for key safety outcomes in i) ARISTOTLE, ii) CPRD Aurum trialmatched cohort, iii) CPRD Aurum trial-matched with TTR<0.75, and iv) CPRD Aurum trialmatched with TTR≥0.75. For the analysis by TTR inverse probability of treatment weighting was applied to the apixaban users targeting the treatment effect in the warfarin users with TTR < 0.75 and TTR ≥0.75. Cl=confidence interval; CPRD=Clinical Practice Research Datalink; HR=hazard ratio; TTR=time in therapeutic range. Sensitivity analyses Table A7 in S3 Appendix shows the proportion of patients switching treatment. A higher proportion of patients on warfarin switched to an alternative OAC during follow-up compared with those on apixaban (16.3% vs 6.1%). Comparing patients who switched treatment during follow-up with those that continued on index treatment (Table A8 in S3Appendix) suggests possible selection bias due to attrition in on-treatment analyses with median TTR markedly lower in warfarin users who switched treatments compared with persistent warfarin users (median TTR 0.64 vs 0.78). On-treatment analyses would likely be biased against apixaban since patients doing badly on warfarin (i.e., with low TTR) who would be more likely to experience events in the warfarin arm would be censored at treatment switch. On-treatment analyses censoring around treatment switch or discontinuation are presented for the effectiveness analyses in the appendix (Table A6 in S3 Appendix); the results show evidence of the expected attrition bias against apixaban when compared with the ITT results in Figure 2, for example HR for stroke/SE is 1.04 (0.86, 1.25) in the on-treatment compared with 0.98 (95% CI 0.82, 1.19) in the ITT analysis. Repeating the analysis with start of study period shifted forwards a year to investigate the impact of inclusion of early adopters yielded similar results to the primary analysis (Table A9 in S3 Appendix). Prior INR control was not included in the propensity score models for the VKA-experienced due to a high rate of missing prior INR data (missing for 34% in the apixaban arm). A post-hoc sensitivity

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

analysis including a prior INR control variable in the PSM gave results consistent with the primary results [Stroke/SE HR 95%CI 1.02 (0.86,1.21)]. Details of this post hoc analysis are in S3 Appendix. Discussion In our emulation of ARISTOTLE using UK routinely-collected healthcare data we found results that met our predefined criteria for comparability with the trial. We saw non-inferiority of apixaban vs warfarin for prevention of stroke or systemic embolism, all-cause mortality, and major bleeding, but did not see superiority of apixaban vs warfarin for these outcomes as was seen in ARISTOTLE. We found higher TTR in the patients using warfarin in our cohort compared with the warfarin arm of ARISTOTLE (median 0.76 vs 0.66). Our analysis by TTR showed that in patients well-controlled on warfarin (TTR ≥ 0.75) warfarin is superior to apixaban whereas in patients not well-controlled on warfarin (TTR < 0.75) apixaban is non-inferior. We saw evidence suggesting sub-optimal dosing of apixban in our cohort with approximately 10% of patients in the apixban arm prescribed the reduced dose without meeting the criteria for the reduced dose. We found the differences in the overall treatment-effect estimates between our cohort and ARISTOTLE may be explained by: the lower proportion of Asian patients in our cohort, differences in INR control in the warfarin arm of our cohort compared with ARISTOTLE, and the higher proportion of patients prescribed a reduced dose of apixaban in our cohort compared with ARISTOTLE. Our findings are consistent with a UK study of ischemic stroke which compared DOACs with warfarin [29]. A Danish study found similar results to ours for stroke/SE [30] although they found apixaban users had a lower risk of death, a study of US claims data [31] also found apixaban was associated with a lower risk of death. A systematic review and meta-analysis of 16 studies [32] found pooled results for stroke and ICH that were consistent with ours. One study (in US claims data) also aimed to replicate ARISTOTLE [33, 34] and in contrast to our study found superiority for apixaban for stroke/SE, which may be linked to population differences such as lower TTR in US patients on

warfarin [35] and differences in ethnicity. None of these studies matched to the ARISTOTLE trial

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

participants, included prevalent users, or looked at how warfarin control impacted results. Further details on these studies including design and key results are summarized in Table A10 in S3 Appendix. A key strength of our study was the use of a framework which sampled prevalent users (the continuing users of warfarin in this study) in a way that avoided selection bias facilitating the construction of a cohort of patients similar to the target trial population, which included both new users of apixaban and warfarin (VKA-naïve) and patients with prior VKA exposure (VKA-experienced) that were randomised to stay on warfarin or switch to apixaban. The use of propensity score matching, stratified by treatment history, enabled us to select a matched cohort well balanced on important covariates. The successful emulation of ARISTOTLE by our study shows that valid treatment effects can be obtained for important outcomes with OACs using non-interventional methods with routinely collected clinical data. Having validated this framework, in future studies we can look at the effectiveness of oral anticoagulants in AF patient groups not included or underrepresented in the RCT such as elderly patients and those at increased bleeding risk. We also recommend future analyses with an extended follow-up period compared with this study to compare the long term outcomes seen in the non-interventional cohort with projected long-term outcomes from the RCT. An additional strength of our study was the ability to explore the quality of warfarin treatment in our cohort and the impact of INR control on the treatment effect estimates. Our finding that the benefits of apixaban vs warfarin depended on the quality of INR control in the warfarin arm answers questions raised in the NICE premeeting briefing which looked at apixaban in the NVAF population and noted the TTR seen in ARISTOTLE "may be lower than what is typical in UK clinical practice" and "apixaban compared with well-controlled warfarin (TTR 75% or more) may not be superior in the long term" [8]. ARISTOTLE presented outcomes by centre (for example hospital) TTR quartile and did not show a signal of treatment efficacy differing by centre TTR quartile. We were able to use inverse

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

probability of treatment weighting to estimate the treatment effect in the different warfarin TTR groups. Our findings may help inform choice of treatment in the context of prior warfarin treatment and availability of INR measurements. Whilst our study aimed to emulate ARISTOTLE using suitable methods there were several limitations. Some of the criteria assessed for ARISTOTLE eligibility may not be well recorded in CPRD leading to a risk of misclassification. Furthermore, misclassification of ARISTOTLE eligibility criteria and baseline covariates could be differential by treatment in the VKA-experienced patients if criteria such as renal function are more likely to be checked before changing treatment. However, the most important risk factors for the primary outcome of stroke (the components of CHA<sub>2</sub>DS<sub>2</sub>-VASc stroke risk score) are mostly well recorded in CPRD Aurum and HES. Our cohort did not attempt to match the trial on the use of concomitant medications in order for our cohort to reflect typical UK prescribing. In ARISTOTLE 31% of participants were using aspirin and 11% using amiodarone at baseline whereas, in our cohort only 6% were recorded as using aspirin and 4% amiodarone. Amiodarone potentiates the effects of warfarin and concomitant use of amiodarone with DOACs is associated with increased risk of major bleeding [36], whilst concomitant use of aspirin increases the risk of bleeding for both warfarin[37] and DOACs [38]. The difference in concomitant medication usage between our cohort and the trial population may explain some of the observed differences in treatment effects. A key limitation of our study was the inability to match ARISOTLE on ethnicity meaning the CPRD Aurum cohort included a low number of patients from Asian and Hispanic groups when compared with the RCT (14.5% of participants in ARISTOTLE were Asian compared to 2.4% in our ARISTOTLEanalogous CPRD cohort). There are known racial differences in the treatment effects of OACs with Asian patients experiencing a higher risk of haemorrhagic stroke and intracranial haemorrhage compared with White patients; in ARISTOTLE Asian participants experienced double the risk of stroke or systemic embolism when on warfarin therapy when compared with White participants

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

[37]. The reasons for the increased risk of bleeding associated with warfarin therapy in Asian patients is hypothesised to be associated with differences in drug metabolism and prevelance of cerebral microbleeds [38]. The difference in proportion of Asian patients between our cohort and ARISTOTLE is therefore likely to explain some of the differences in treatment effects seen and limits the generalisability of our study, with the results of our study of most relevanance to White patients. This limitation on ethnicity arose from the data source used and time period studied (patients with AF in CPRD Aurum 2013-2019) which had a low proportion of Asian patients, likely due to AF being associated with older age combined with a lower prevalence of AF in Asian patients compared with White patients [38]. Whilst CPRD Aurum is largely representative of the UK population in relation to ethnicity [39], diversity is still limited for older individuals. Despite this, CPRD Aurum has shown to be a useful resource for investigating treatment effects in different ethnic groups for indications such as hypertension which is more prevalent and occurs at a younger age in ethnic minority groups, with similar trial replication methods used to compare antihypertensive treatment effects in underrepresented ethnic groups [40]. The approach our study used for handling missing data on baseline covariates relied on assumptions on the relationship between missingness, treatment, and outcomes which may not be valid; however the low proportion of missing data means that this is unlikely to have impacted the results. In the coarsened exact matching step the choice of variables will have an impact on the resulting cohort selected meaning a different combination of variables could lead to different results. There is a risk that residual confounding may be present despite the use of propensity score matching. The use of propensity score matching also has the potential to introduce bias by dropping patients from the cohort [19], however propensity score matching is well suited to the process of trial emulation including prevalent users and a low number of apixaban users were dropped due to unsuccessful matching. The inclusion of prevalent users of warfarin in the cohort risks the introduction of selection bias[20,21]; this was avoided by use of a method shown to produce unbiased estimates in a simulation study [21]. We found consistent results between our new and prevalent user strata

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

across multiple outcomes providing reassurance the method used was likely to have successfully avoided selection bias. Apixaban along with other DOACs were rapidly adopted as preferred first line OAC in AF during the study period; it was therefore not possible to match on calendar date leading to a difference in follow-up time between the treatment arms in our cohort. A higher proportion of warfarin users switched to alternative OAC during follow-up compared with those prescribed apixaban (16% vs 6%). The impact of this differential switching during follow-up was addressed in the sensitivity analyses. The availability of new alternative treatments during the study period also means there is a risk of channelling bias in that over time the patients still on warfarin are more likely to be those doing well on warfarin. INR control prior to the index date was not included in the propensity score for the prevalent users due to a high rate of missing data, however, other variables associated with poor INR control were included in the models and an exploratory post-hoc analysis including a variable for poor INR control gave results consistent with the primary results. Adherence to treatment was difficult to assess in our study due to automatic repeat prescriptions; treatment persistence was more useful in providing a measure of pattern of medicine use over time. In the analysis by TTR the adherence of patients using apixaban was not accounted for, however, a previous UK study showed apixaban had higher adherence than VKAs [41] meaning we would expect to see better effectiveness outcomes in apixaban. Futhermore, the use of IPTW in the analysis by TTR means predictors of poor adherence are likely to have been balanced between treatments. The analysis of TTR is limited by this being a post-baseline measure available for only one treatment arm; this limitation was also evident in the RCTs of DOACs vs warfarin and is mitigated in our study through the use of IPTW. Sensitivity analyses in our cohort using an on-treatment censoring scheme showed evidence of attrition bias. The regular measurement of INR and availability of alternative anticoagulants makes warfarin therapy particularly prone to attrition bias since a patient may be

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661 662

663 664

665

666

References

more likely to switch to a DOAC if their INR is frequently out of the optimal range or if they have not been adhering to scheduled INR testing. To conclude, we found that applying a reference trial emulation approach allowed us to emulate a landmark randomized trial of apixaban versus warfarin using UK non-interventional data, with results meeting pre-specified benchmarking criteria based on the reference trial results. This trial emulation method provides valid treatment effect estimates for apixaban compared to warfarin and can be used to determine risks and benefits of AF medications in people treated in routine clinical care. This study demonstrates a successful real world application of novel methods that have been proposed for the inclusion of prevalent users in observational studies, with the application of an adaptation to mimic the screening process making the method suitable for emulation of RCTs that include prevalent users. These methods could be adapted for emulation of RCTs in other therapeutic areas and for looking at patient groups under-represented or excluded from RCTs. We further showed that when compared to well-controlled warfarin therapy, apixaban was associated with harmful treatment effects. The weaker overall treatment benefit observed in our cohort appears to be due to a higher proportion of patients with well-controlled warfarin in the UK clinical context, compared with the trial. NICE guidance (2021) advises that for patients already on VKA their TTR should be taken into account when deciding whether to switch to a DOAC; our findings support the option of staying on VKA for those patients happy with their treatment and who have TTR  $\geq$  0.75. S1: STROBE checklist S2: ISAC protocol for the ARISTOTLE emulation study S3: Appendix containing supporting information

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

[1] Adderley NJ, Ryan R, Nirantharakumar K, Marshall T. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2019 Jan; 105(1):27-33. doi: 10.1136/heartjnl-2018-312977. [2] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8. doi: 10.1161/01.str.22.8.983. [3] Friberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014 Sep;45(9):2599-605. doi: 10.1161/STROKEAHA.114.006070. [4] Ali AN, Abdelhafiz A. Clinical and Economic Implications of AF Related Stroke. J Atr Fibrillation. 2016 Feb. 29;8(5):1279. doi: 10.4022/jafib.1279. [5] Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013; 40(4):227–39. doi: 10.1159/000343667. [6] Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. 053 Factors affecting quality of warfarin anticoagulation in patients with atrial fibrillation: insights from affirm. Heart. 2012;98:A32. doi:10.1136/heartjnl-2012-301877b.53. [7] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92, doi: 10.1056/NEJMoa1107039. [8] European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report Eliquis apixaban. Procedure No.:EMEA/H/C/002148/X/04/G. EMA/641505/2012, 2012, page 35. Available from: https://www.ema.europa.eu/en/documents/variation-report/eliquish-c-2148-x-0004-g-epar-assessment-report-extension\_en.pdf [9] National Institute for Health and Clinical Excellence. Premeeting briefing. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Issue date: November 2012. Available from:

perpetuity.

It is made available under a CC-BY 4.0 International license .

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

https://www.nice.org.uk/guidance/ta275/documents/stroke-and-systemic-embolism-preventionnonvalvular-atrial-fibrillation-apixaban-premeeting-briefing2 [10] Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, et al. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 Mar 9.143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17. [11] Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, et al. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. Eur Respir J. 2021 Mar 25;57(3):2001586. doi: 10.1183/13993003.01586-2020. [12] Dahabreh IJ, Robins JM, Hernán MA. Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations. Epidemiology. 2020 Sep;31(5):614-619. doi: 10.1097/EDE.00000000000001231. [13] Baptiste PJ, Wong A YS, Schultze A, Clase CM, Leyrat C, Williamson E, et al. Comparative effectiveness of ARB and ACEi for cardiovascular outcomes and risk of angioedema among different ethnic groups in England: an analysis in the UK Clinical Practice Research Datalink with emulation of a reference trial (ONTARGET). medRxiv preprint 2024 Jan 17 doi: doi:10.1101/2024.01.17.24301397. [14] Powell EM, Douglas IJ, Gungabissoon U, Smeeth L, Wing K. Real-world effects of medications for stroke prevention in atrial fibrillation: protocol for a UK population-based non-interventional cohort study with validation against randomized trial results. BMJ Open 2021;11:e042947. doi:10.1136/bmjopen-2020-04294. [15] Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019 Dec 1;48(6):1740-1740g. doi: 10.1093/ije/dyz034. [16] Rose M, Beasley N. Center for Drug Evaluation and Research Application number: 202155Orig1s000 MEDICAL REVIEW(S). Available for download at: https://www.accessdata.fda.gov/drugsatfda docs/nda/2012/202155Orig1s000TOC.cfm

perpetuity.

It is made available under a CC-BY 4.0 International license.

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

[17] Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7;36(46):3268-75. doi: 10.1093/eurheartj/ehv447. [18] Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864-72. doi: 10.1093/eurheartj/ehu046. [19] Jacus SM, King G, Porro G. Causal Inference without Balance Checking: Coarsened Exact Matching Political Analysis. 2012;20(1):1-24. doi:10.1093/pan/mpr013 [20] Suissa S, Moodie EE, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):459-468. doi: 10.1002/pds.4107. [21] Webster-Clark M, Mavros P, Garry EM, Stürmer T, Shmuel S, Young J, et al. Alternative analytic and matching approaches for the prevalent new-user design: A simulation study. Pharmacoepidemiol Drug Saf. 2022 Jul;31(7):796-803. doi: 10.1002/pds.5446. [22] Austin, P.C. (2009), Some methods of propensity-score matching had superior performance to others: results of an empirical Investigation and Monte Carlo simulations. Biom. J. 2009 Feb;51(1): 171-84. doi: 10.1002/bimj.200810488 [23] Woodfield R, Grant I, UK Biobank Stroke Outcomes Group, UK Biobank Follow-Up and Outcomes Working Group, Sudlow CL. Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group. PLoS One. 2015 Oct 23;10(10):e0140533. doi: 10.1371/journal.pone.0140533. [24] Austin P.C, Small DS. The use of bootstrapping when using propensity-score matching without replacement: A simulation study. Stat Med. 2014 Oct 30; 33(24), 4306–19. doi: 10.1002/sim.6276. [25] Abadie A., Spiess J. Robust Post-Matching Inference. Journal of the American Statistical Association, 117:538, 983-995, doi: 10.1080/01621459.2020.1840383[26] Lobo FS, Wagner S, Gross

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res SocialAdm Pharm. 2006 Mar;2(1):143-51. doi: 10.1016/j.sapharm.2005.12.001.[27] Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983 Apr;70(1):41-55. doi: 10.1093/biomet/70.1.41. [28] Blake HA, Leyrat C, Mansfield KE, Seaman S, Tomlinson LA, Carpenter J, et al. Propensity scores using missingness pattern information: a practical guide. Stat Med. 2020 May 20;39(11):1641–1657. doi: 10.1002/sim.8503. [29] Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018 Jul 4; 362:k2505 doi:10.1136/bmj.k2505. Erratum in: BMJ. 2018 Oct 18;363:k4413. [30] Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016 Jun 16;353:i3189. doi:10.1136/bmj.i3189. [31] Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017 Jun 2;117(6):1072-1082. doi:10.1160/TH17-01-0068 [32] Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. [33] Franklin J, Brigham and Women's Hospital. Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04593030 [34] Wang SV, Schneeweiss S, RCT-DUPLICATE initiative, Franklin JM, Desai RJ, Feldman W, et al. Emulation of Randomized Clinical Trials With Nonrandomized Databse Analyses: Results of 32 Clinical Trials. JAMA. 2023 Apr 25;329(16):1376-1385. doi:10.1001/jama.2023.4221.

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

[35] Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul;170(1):141-148.e1. doi: 10.1016/j.ahj.2015.03.017. [36] Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017 Oct 3;318(13):1250-1259. doi: 10.1001/jama.2017.13883. [37] Schaefer JK, Li Y, Gu X, et al. Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. JAMA Intern Med. 2019;179(4):533-541. doi:10.1001/jamainternmed.2018.7816 [38] Almas T, Musheer A, Ejaz A, et al. Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis. Int J Cardiol Heart Vasc. 2022 Mar 26;40:101016. doi: 10.1016/j.ijcha.2022.101016. [37] Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol. 2014 May;11(5):290-303 (2014). doi: 10.1038/nrcardio.2014.22. [38] Kim HK, Tantry US, Smith SC, et al. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thromb Haemost. 2021 Apr;121(4):422-432. doi: 10.1055/s-0040-1718729. [39] Gillott RG, Willan K, Kain K, et al. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. Europace. 2017 Mar 1;19(3):356-363. doi: 10.1093/europace/euw010. [39] Shiekh, S.I., Harley, M., Ghosh, R.E. et al. Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom's Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). Popul Health Metrics 21, 3 (2023). https://doi.org/10.1186/s12963-023-00302-0

798

799

800


801

802


803

[40] Paris J Baptiste, Angel YS Wong, Anna Schultze, et al. Comparative effectiveness of ARB and ACEi for cardiovascular outcomes and risk of angioedema among different ethnic groups in England: an analysis in the UK Clinical Practice Research Datalink with emulation of a reference trial (ONTARGET). medRxiv 2024.01.17.24301397; doi: https://doi.org/10.1101/2024.01.17.24301397 [41] Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020 Jan;106(2):119-126. doi: 10.1136/heartjnl-2019-315307.

New users of apixaban (VKA-naïve) propensity score matched 1:1 to new users of warfarin.





ii. Pool of prevalent warfarin users containing all warfarin prescription dates in the study period for each warfarin user sampled without replacement by treatment history to ensure similar duration of prior VKA exposure for the prevalent users in the apixaban and warfarin CPRD Aurum arms:



- 10 warfarin continuers selected for each VKA-experienced apixaban 'switcher'
- Matching started with 'earliest' (ie. shortest treatment history)
   apixaban switcher to avoid selection bias\*
- Trial-eligibility of warfarin users hidden until the point of selection to avoid selection bias
- Any warfarin users selected and not trial-eligible at that timepoint (treatment history) were dropped from the pool of potential comparators and an alternative warfarin continuer sampled
- The sampling process can be seen as analogous to the screening process of a RCT with potential participants only having one chance to pass screening.

iii. VKA-experienced apixaban users propensity score matched 1:1 to the treatment-history matched comparator pool. Propensity scores were calculated stratified by treatment history strata and patients matched within treatment history strata.








Fig3




Fig4